- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | CG Oncology Inc.: CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024 | 1 | GlobeNewswire (USA) | ||
| 24.04. | CG Oncology Inc.: CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024 | 2 | GlobeNewswire (USA) | ||
| 28.03. | CG Oncology Inc.: CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 26.03. | CG Oncology, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 20.02. | Cantor starts CG Oncology at overweight, cites bladder cancer treatment | 2 | Seeking Alpha | ||
| 20.02. | Goldman Sachs starts CG Oncology stock with neutral rating, $42 price target | 2 | Investing.com | ||
| 20.02. | Morgan Stanley rates CG Oncology shares Overweight on positive results | 5 | Investing.com | ||
| 16.02. | CG Oncology, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.02. | CG Oncology stock initiated with buy rating and $75 target by H.C. Wainwright | 3 | Investing.com | ||
| 30.01. | CG Oncology, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.01. | US IPO Weekly Recap: Biotech CG Oncology pops 96% in a 7 IPO week | 3 | Renaissance Capital | ||
| 26.01. | CG Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 26.01. | CG Oncology: Triumphaler Börsengang - Aktie zieht mächtig an | 658 | finanztreff.de | CG Oncology hat bei seinem Gang an die Nasdaq einen fulminanten Börsenstart hingelegt, der die Erwartungen deutlich übertraf. Das Engagement führender Biotech-Investoren unterstreicht dabei die vielversprechende... ► Artikel lesen | |
| 26.01. | Irres Biotech-IPO: Newcomer CG Oncology explodiert knapp 96 Prozent | 584 | Der Aktionär | Mit dem amerikanischen Krebs-Spezialisten CG Oncology ist das erste Biotechnologie-IPO des Jahres 2024 an der Nasdaq am Donnerstag erfolgreich über die Bühne gegangen. Das Interesse an dem Newcomer... ► Artikel lesen | |
| 25.01. | Biotech CG Oncology Doubles in Debut After Expanded IPO | 2 | BNN Bloomberg | ||
| 25.01. | CG Oncology, first biotech IPO for 2024, surges on trading debut | 2 | Seeking Alpha | ||
| 25.01. | CG Oncology valued at $1.75 billion in strong market debut | 3 | Reuters | ||
| 25.01. | Bladder cancer biotech CG Oncology prices further upsized IPO above the range at $19 | 2 | Renaissance Capital | ||
| 25.01. | In first biotech IPO of the year, CG Oncology overshoots estimates by bringing in $380M | 4 | FierceBiotech | ||
| 25.01. | CG Oncology Prices Upsized 20M Share IPO at $19/sh | 2 | Investing.com |
Seite:
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ALPINE IMMUNE SCIENCES | 60,00 | -1,64 % | Aktien New York: Dow erholt sich vor Start in die Berichtssaison | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben sich am Donnerstag im Handelsverlauf von ihrer anfänglichen Schwächephase erholt. Der Dow Jones Industrial notierte zuletzt 0,12 Prozent im Plus bei 38... ► Artikel lesen | |
| CYTOKINETICS | 60,00 | +4,35 % | (CYTK) - Analyzing Cytokinetics' Short Interest | ||
| REGULUS THERAPEUTICS | 2,660 | +22,02 % | Regulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates | Positive topline data from the second cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Oversubscribed... ► Artikel lesen | |
| ARVINAS | 32,420 | -0,18 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| JANUX THERAPEUTICS | 62,43 | +7,29 % | Janux Therapeutics jumps as much as 28% on heels of Deciphera buyout deal | ||
| RAPT THERAPEUTICS | 7,250 | 0,00 % | RAPT Therapeutics, Inc.: RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients | - Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status - Confirmed ORR of 17.4% in subset of patients with PD-L1+ disease - Confirmed ORR of 22.2% in... ► Artikel lesen | |
| KURA ONCOLOGY | 18,750 | +1,13 % | Kura Oncology, Inc. - 8-K, Current Report | ||
| 4D MOLECULAR THERAPEUTICS | 26,370 | +4,02 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic... ► Artikel lesen | |
| CARIBOU BIOSCIENCES | 3,655 | -0,95 % | Caribou Biosciences, Inc.: Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus | -- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial safety... ► Artikel lesen | |
| PROTAGONIST THERAPEUTICS | 24,000 | +1,69 % | Protagonist Therapeutics, Inc.: Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data | On track to achieve 250 patient enrollment target in March 2024Top-line data for 32-week primary endpoint expected in the first quarter of 2025NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist... ► Artikel lesen | |
| STOKE THERAPEUTICS | 11,400 | +9,62 % | Stoke Therapeutics, Inc. - 8-K, Current Report | ||
| NURIX THERAPEUTICS | 12,720 | -2,90 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update | Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies... ► Artikel lesen | |
| ALVOTECH | 13,700 | +1,48 % | Alvotech To Manufacture Its High-concentration Interchangeable Biosimilar To Humira For Quallent | PETAH TIKVA (dpa-AFX) - Alvotech (ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), said, under the recently announced U.S. strategic partnership agreement... ► Artikel lesen | |
| PEPGEN | 14,310 | +3,47 % | PepGen Inc.: PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy | BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming... ► Artikel lesen | |
| QIAGEN | 39,585 | +1,29 % | Ihre wichtigsten Termine: Heute im Fokus: Zahlen von Porsche AG, Philips, Qiagen, Vivendi und Bawag Group | © Foto: Porsche AG NewsroomGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:55... ► Artikel lesen |
CG ONCOLOGY INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 39,500 Euro und damit -2,76 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
